Los Angeles, CA, March 10, 2025 – Tetrous, Inc., a Sherman Oaks start up focused on bone-to-tendon healing following orthopedic surgery, is pleased to announce the successful closure of its Series A financing round, raising a total of $6,500,000. This round of financing was a Reg D offering available to accredited investors. It attracted a diverse group of investors, including a significant investment (over 50% of the raise) from strategic partners including our USA and Australian manufacturing and distribution partners, as well as investments from the management team, and existing shareholders. The round was expanded twice from the initial $5,000,000 target due to overwhelming interest and support from existing investors, strategic partners and new investors.
Investors were enthusiastic about how Tetrous is redefining bone to tendon repair, addressing a major unmet need for biological regeneration of the anatomic structure that provides proper transmission of tensile load from soft tissues to bone, ie. the enthesis. The enthesis is a significant point of failure in rotator cuff repairs, which have a reported failure rate of 13%-94%!
The Series A funds are being used to increase the company’s market penetration, develop further clinical data showing the improvement in outcomes for patients, and expand surgical applications of the company’s patented technology, including for hip, knee, ankle and elbow procedures with existing and new product offerings.
“We are thrilled with the success of this financing round and the confidence our existing shareholders and strategic partners have placed in us,” said Bradley Patt, PhD., CEO of Tetrous. “This funding is enabling us to further enhance our product offerings, broaden our reach, and continue to deliver exceptional value to our customers. It’s All About the Enthesis.”
“I am excited to further our partnership with Tetrous as they continue to prove that biologic healing is the future of bone-tendon healing” said Simon Berry, CEO of Tetrous Manufacturing and Distribution partners Australian Biotechnologies (Sydney, Australia) and Origin Biologics (Las Vegas, NV, USA) and Director of ABT Healthcare, a Sydney based Investment Trust. “They have demonstrated an impressive vision for growth, and we are thrilled to support their continued success.”
The EnFix® family of allograft products are designed to enhance healing at the enthesis, where failure often occurs. The implants are 100% demineralized bone fiber (DBF), providing osteoinductivity and osteoconductivity, resulting in optimal biologic performance with minimal disruption to current surgical techniques.
###
About Tetrous, Inc.
Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery. The Company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in over 150,000 implants in spine applications. Tetrous enjoys significant IP protection for its EnFix family of products with multiple issued patents and, additionally, has an exclusive license to the demineralized bone fiber technology used in its products for sports medicine applications from TheraCell, an ISTO Biologics Company.
About ABT Healthcare
ABT Healthcare is based in Sydney, Australia and is a private investment fund that invests in early stage medtech companies. ABT Healthcare fund invests internationally across multiple market segments. The Fund is led by Lawrence Myers, Jerome Goldberg and Simon Berry. Inquiries can be made to simon.berry@abthealth.com.au.
EnFix®, EnFix RC™, EnFix TAC™, and It’s All About the Enthesis™ are trademarks of Tetrous, Inc.
FormLok™ is a trademark of TheraCell, Inc., an Isto Biologics company.
For more information visit www.tetrous.com and follow us on LinkedIn (www.linkedin.com/company/tetrous).
